BBI
TVRD

Baxter Bros Inc’s Tvardi Therapeutics TVRD Stock Holding History

Baxter Bros Inc’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-313
Closed -$242K – 118
2019
Q2 		$242K Sell
313
-34
-10% -$23.9K 0.06% 104
2019
Q1 		$245K Hold
347
– – 0.06% 102
2018
Q4 		$162K Hold
347
– – 0.04% 105
2018
Q3 		$299K Buy
+347
New +$251K 0.07% 98

Other funds holding TVRD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Baxter Bros Inc's TVRD Position: Q3 2019 in Review

Baxter Bros Inc sold out of Tvardi Therapeutics (TVRD) in Q3 2019, closing a stake of 313 shares — an estimated $242K sold.

Baxter Bros Inc first reported a position in TVRD in Q3 2018 and held it in 4 quarters. The position peaked at $299K in Q3 2018. 144 funds tracked by Wall St. Rank hold TVRD as of Q3 2019.

  • Baxter Bros Inc reported no remaining Tvardi Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Baxter Bros Inc sold 313 Tvardi Therapeutics shares in Q3 2019, an estimated $242K.
  • Baxter Bros Inc first reported a position in Tvardi Therapeutics in Q3 2018 and held it in 4 quarters.
  • Baxter Bros Inc's Tvardi Therapeutics position peaked at $299K in Q3 2018.
  • 144 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2019.

Based on Baxter Bros Inc's 13F filing for Q3 2019, filed 21 Oct 2019.